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ABSTRACT
Objectives The objective of this study was to examine
the associations of brain tumours with radio frequency
(RF) ﬁelds from mobile phones.
Methods Patients with brain tumour from the
Australian, Canadian, French, Israeli and New Zealand
components of the Interphone Study, whose tumours
were localised by neuroradiologists, were analysed.
Controls were matched on age, sex and region and
allocated the ‘tumour location’ of their matched case.
Analyses included 553 glioma and 676 meningioma
cases and 1762 and 1911 controls, respectively. RF dose
was estimated as total cumulative speciﬁc energy
(TCSE; J/kg) absorbed at the tumour’s estimated centre
taking into account multiple RF exposure determinants.
Results ORs with ever having been a regular mobile
phone user were 0.93 (95% CI 0.73 to 1.18) for glioma
and 0.80 (95% CI 0.66 to 0.96) for meningioma. ORs for
glioma were below 1 in the ﬁrst four quintiles of TCSE
but above 1 in the highest quintile, 1.35 (95% CI 0.96 to
1.90). The OR increased with increasing TCSE 7+ years
before diagnosis (p-trend 0.01; OR 1.91, 95% CI 1.05 to
3.47 in the highest quintile). A complementary analysis in
which 44 glioma and 135 meningioma cases in the most
exposed area of the brain were compared with gliomas
and meningiomas located elsewhere in the brain showed
increased ORs for tumours in the most exposed part of
the brain in those with 10+ years of mobile phone use
(OR 2.80, 95% CI 1.13 to 6.94 for glioma). Patterns for
meningioma were similar, but ORs were lower, many
below 1.0.
Conclusions There were suggestions of an increased
risk of glioma in long-term mobile phone users with high
RF exposure and of similar, but apparently much smaller,
increases in meningioma risk. The uncertainty of these
results requires that they be replicated before a causal
interpretation can be made.
INTRODUCTION
Rapid increases in mobile phone use have generated
concerns about possible health effects of exposure
to radio frequency (RF) electromagnetic ﬁelds. A
multinational caseecontrol study, Interphone,
1
aimed to evaluate the association of brain, acoustic
nerve and parotid gland tumours with RF exposure
from mobile phone use. Most epidemiological
studies, including Interphone, have only reported
risk in relation to mobile phone use history.
2e20
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What this paper adds
< Previous epidemiological studies of mobile
phone use and brain cancer risk have used
information on mobile phone use as a proxy
measure of exposure to radio frequency ﬁelds
from mobile phones.
< Most studies have not observed increased ORs
in relation to ever having been a mobile phone
user. There were suggestions, however, of an
increased risk of glioma in long-term and heavy
users, though biases and errors prevent a causal
interpretation.
< The relationship between radio frequency
energy absorbed at the tumour location and
mobile phone use history is complex. In addition
to amount of use, it depends on phone type,
network properties, conditions of use and
tumour location. The present paper is the ﬁrst
to use estimates of radio frequency energy
deposition at the centre of tumours in the brain
as a measure of radio frequency dose.
< An increased risk of glioma was seen in
individuals at the highest quintile of radio
frequency dose, though reduced risks were
seen in the four lower quintiles. When risk was
examined as a function of dose received in
different time windows before diagnosis, an
increasing trend was observed with increasing
radio frequency dose (p¼0.01) for exposures
7 years or more in the past.
< Caseecase analyses, made possible by tumour
localisation, indicated an increased risk in the
most exposed region of the brain compared with
other areas among long-term users.
< Patterns of risk for meningioma in relation to
radio frequency dose were similar, although
increases in risk were much smaller than for
glioma, and not statistically signiﬁcant.
< Our results suggest that there may be an
increase in risk of glioma in the most exposed
area of the brain among long-term and heavy
users of mobile phones. These results are
uncertain (in light of the uncertainties associated
with tumour centre localisation, radio frequency
dose estimation and sample size) and require
replication before they can be taken to indicate
a causeeeffect relationship.
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Original articleThe relationship between RF energy absorbed at the tumour
location and mobile phone use history is complex.
21e23 In
addition to amount of use, it depends on phone type, network
properties, conditions of use and tumour location.
24 Thus,
Interphone attempted a systematic and detailed evaluation and
quantiﬁcation of factors thought to inﬂuence RF dose from
mobile phones in different brain locations. This necessitated
identiﬁcation of probable determinants of RF Speciﬁc Absorp-
tion Rate (SAR) during protocol development and questionnaire
design and collection and analysis of information to evaluate the
importance of each factor. An algorithm was developed to
evaluate total RF dose absorbed at speciﬁc locations in the
brain
24 and applied to Interphone study subjects in ﬁve countries
to estimate RF dose at the tumour location. This paper presents
the results of analysis of associations of glioma and meningioma
risk with these dose estimates.
MATERIALS AND METHODS
Analyses used data from the ﬁve Interphone countriesd
Australia, Canada, France, Israel and New Zealanddthat agreed
to transfer their data to Barcelona when EC, the Interphone
Principal Investigator, relocated there. Interphone is an
international, population-based caseecontrol study based on
a common protocol.
1 25
Deﬁnition of cases and controls
Cases were patients aged 30e59 years with brain glioma or
meningioma diagnosed between 2000 and 2004. Cases were
ascertained actively from neurosurgical and oncological facilities,
and completeness of ascertainment checked through secondary
sources.
1 All diagnoses were histologically conﬁrmed or based on
unequivocal diagnostic imaging.
The original Interphone protocol called for selection of one
control per case from a locally appropriate population-based
sampling frame. Matching variables were age (within 5 years), sex,
region of residence and, in Israel, country of birth. Controls tended
to be interviewed later than cases.
1 As mobile phone use increased
during the study period, later interviews could have spuriously
increased exposure prevalence among controls. To minimise
resulting bias, controls in all countries were post-hoc matched
to cases with tumour localisation using an algorithm that opti-
mised matching on interview time and age within strata deﬁned
by sex, region and, in Israel, country of birth. Date of case diag-
nosis was used as the reference date for cases and controls in
each matched set. Each control was assigned the tumour location
of his or her matched case as a reference location. To maximise
statistical power, all interviewed and eligible controls were
matched to glioma and meningioma cases separately, provided
they had been interviewed within 1 year of the of the cases’
interview; 1439 controls are thus included in both glioma
and meningioma analyses. Number of controls per case varied
from 1 to 19 (median 3) for glioma and 1 to 23 (median 2) for
meningioma.
Collection of information
Detailed information on past mobile phone use was collected
by interview with study subjects or proxies.
1 This included
amount, timing and conditions of mobile phone use, phone
models and operators. A catalogue of phones was used to assist
subjects in identifying phones they had used. In each country,
historical information was obtained from mobile phone
operators on communication systems and frequencies used,
introduction of adaptive power control and use of discontinuous
transmission.
Tumour localisation
Since intracranial RF energy deposition from mobile phones
is non-uniform, with most of the energy absorbed near the
phone,
23 each tumour’s centre was estimated so that RF dose at
that location could be estimated. Neuroradiologists in each
centre reviewed radiological images (MRI and CT scans) when
possible and recorded tumour location and their best guess
at the tumour centre (referred to as ‘centre estimated by
neuroradiologist’) on a generic three-dimensional (3-D) grid
map of the human brain, the Gridmaster, made up of 1 cm
cubes.
26 A detailed methodological description will be published
separately.
27
When images were not available, neuroradiologists used
radiology reports to prepare a 3-D representation of the tumour
volume in the Gridmaster (all cases in Israel and 12% of cases
elsewhere) (table AI). We then developed a computer algorithm
to estimate tumour centre (referred to as ‘centre estimated by
computer algorithm’). For glioma cases, the Euclidean distances
from each Gridmaster cube of the tumour’s 3-D representation
to the others were calculated and the cube(s) at the shortest
distance(s) from others (the ‘centre of gravity’) chosen as the
centre. For meningioma, tumours were separated into those on
the surface of the meninges close to the skull and others. For the
second, the process was as described for glioma; for the ﬁrst, it
included only cubes in the outermost Gridmaster layer. The
program was validated on subjects for whom a neuroradiologist
estimated the centre, with good agreement, particularly for
glioma.
27
RF dose algorithm
An algorithm was developed to estimate dose as cumulative
speciﬁc energy (CSEl,f,s), in joules per kilogram, absorbed at
a given location in the brain (l) for a given frequency band (f)
and communication system (s) (eg, AMPS, Advanced Mobile
Phone System; GSM, Global System for Mobile).
24 CSEl,f,s was
calculated as the sum, over all phones the subject used, of the
product of estimated average SAR received at the tumour’s
location and total call duration in this frequency band and
communication system. Modifying factors were taken into
account: laterality of use, hands-free devices, network charac-
teristics and, where appropriate, frequency of use in urban and
rural settings. Total cumulative speciﬁc energy (TCSE) at the
location was then calculated as the sum, over all frequency
bands and communication systems, of the frequency- and
communication-system-speciﬁc CSEs.
If the subject reported a preferred side of use, 90% of phone
use was assigned to that side of the head and 10% to the other. If
the subject could not answer, or said he or she used it on both
sides, 50% of use was assigned to each side.
Statistical analyses
Analyses were limited to cases with tumour localisation data.
The main analyses used unconditional logistic regression,
stratiﬁed on the matching variables (age, sex and region) and
adjusted for education level and the interaction between study
region and time period of interview (6-month intervals). As the
matching was on variables that were explicitly measured (and
therefore could be controlled in an unconditional analysis),
stratiﬁed unconditional logistic regression was conducted, rather
than conditional logistic regression based on matched sets, to
maximise the number of informative strata in the analyses. This
was important for analyses by time windows as many matched
sets would have been dropped out of these analyses if
conditional logistic regression had been used.
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subjects who reported that they had never used mobile phones
regularly. Sensitivity analyses restricted to regular users, with
the lowest users as the reference category, were also conducted.
Dose variables included TCSE averaged over the estimated
tumour centre (generally one to two cubes of the Gridmaster),
TCSE averaged over the entire tumour volume and CSE for
individual systems deﬁned by frequency band (800e900 and
1800e1900 MHz) and technology type (analogue and digital). In
each analysis, TCSE or CSE was censored 1 year before the
reference date to allow a minimum latent period between ﬁrst
exposure and tumour diagnosis.
Categorical analyses were conducted in quintiles of TCSE or
CSE among regular user controls. In analyses of speciﬁc systems,
mobile phone users who had not used that system were assigned
a CSE of 0 and included in a separate category (eg, ‘non
800e900 MHz’ for analyses of 800e900 MHz). To allow
comparisons with the 13-country Interphone analyses of mobile
phone use,
28 we also analysed quintiles of cumulative call time
(data were too sparse for analyses by deciles).
The main analyses were based on TCSE at the tumour centre
estimated by neuroradiologists when available or by computer
algorithm and took into account laterality of use. We also
assessed the possible effect of RF exposure in different time
periods, by ﬁtting a model in which we considered TCSE
<3 years before the reference date, 3e6 years before and 7+
years before, based on reported mobile phone use in these
periods. As previous studies have raised the issue of risk 10 years
or more after exposure, we originally intended to analyse TCSE
in periods 0e4, 5e9 and 10+ years before the reference date but
could not because of small numbers of subjects in different
TCSE categories in the 10+ years period.
Sensitivity analyses were conducted restricting analyses to
subjects with probable centre estimated by a neuroradiologist;
not taking into account laterality of phone use (50% of CSE was
assigned to each side for all subjects); averaging CSE over the
entire tumour volume; and excluding proxy interviews, subjects
with very high levels of reported phone use (5 h or more per day
in any period) or subjects who reported use of 450 MHz tele-
phones (with little information on spatial SAR distribution, see
Cardis et al
24).
Finally, caseecase analyses were conducted in which mobile
phone use was compared between cases whose probable tumour
centre was in the most exposed brain region and cases whose
tumour centre was elsewhere, using unconditional logistic
regression adjusted for age, sex and region. The most exposed
area was deﬁned as the area with the highest RF SAR from
mobile phones,
23 falling within the 3 dB exposure volume (ﬁgure
AI), without taking into account reported laterality of use or
self-reported amount of mobile phone use. It comprised 230 of
the 1431 Gridmaster cubes, a region comprising about 16% of
the brain volume and absorbing over 50% of the SAR from
mobile phones.
RESULTS
The ﬁve Interphone countries contributing to this analysis
ascertained 1302 cases of glioma, 1199 cases of meningioma and
4838 controls eligible for the study (table AI).
1 Of these, 809
glioma cases and 842 meningioma cases were interviewed and
could be matched to at least one control (table AI). Information
on tumour localisation, communication systems and frequency
bands used was available for 553 glioma cases (42.4% of glioma
cases) and 1762 matched controls (36% of controls), and 676
meningioma cases (56.4% of meningioma cases) and 1911
matched controls (39.5% of controls); these were the subjects
of the primary analyses of RF exposure. The mean age of glioma
cases was 47.2 years and 62% were men; the mean age of
meningioma cases was 49.7 years and 26% were men. The
respective matched controls had similar age and sex
distributions.
We calculated ORs for regular phone use and cumulative call
time without use of hands-free devices in all interviewed
subjects who could be matched to relate results of this ﬁve-
country analysis to those of Interphone as a whole.
28 For glioma,
the OR for regular phone use was 0.92 (95% CI 0.75 to 1.13) and
that for the top category of cumulative call time (735+ h of use)
was 1.17 (95% CI 0.88 to 1.56) (table 1). The most closely
corresponding Interphone results were, respectively, 0.81 (95%
CI 0.70 to 0.94) and, for 735e1639.9 and 1640+ h of use
together, 1.00 (95% CI 0.80 to 1.22). For meningioma, the OR
for regular phone use was 0.80 (95% CI 0.66 to 0.96) and that for
735+ h of use was 1.01 (95% CI 0.75 to 1.36) (table 1) compared
with Interphone results of, respectively, 0.79 (95% CI 0.68 to
0.91) and, for 735e1639.9 and 1640+ h of use together, 0.93
(95% CI 0.73 to 1.19). Results of similar analyses in subjects
with localisation data were not greatly different from those in
all interviewed subjects (table 1). ORs for glioma in subjects
whose tumour centre was also estimated by a neuroradiologist
were higherd1.06 (95% CI 0.77 to 1.47) in regular users and 1.72
(95% CI 1.07 to 2.77) in 735+ h of call time, mainly due to
exclusion of subjects from Israel. Israel contributed 73% of
excluded glioma cases and its ORs for glioma were 0.67 (95% CI
0.43 to 1.05) in regular users and 0.57 (95% CI 0.30 to 1.74) in
735+ h of call time.
TCSE was highly skewed in cases and controls (ﬁgure AII).
Higher proportions of glioma cases than controls had TCSE
above 3500 J/kg. Though there was moderate agreement
between categorisation of subjects by TCSE and cumulative call
time (weighted k 0.68), misclassiﬁcation was non-negligible,
particularly at higher frequency bands.
24 ORs for glioma and
meningioma were below 1 in the ﬁrst four quintiles of TCSE. In
the highest quintile, the OR for glioma was 1.35 (95% CI 0.96 to
1.90) in subjects with tumour localisation and 1.66 (95% CI 1.03
to 2.67) in subjects with centre estimated by a neuroradiologist
(table 2). Corresponding ORs for meningioma were 0.90 (95%
CI 0.66 to 1.24) and 1.01 (95% CI 0.63 to 1.62).
In analyses of TCSE in different time intervals before the
reference date, an increased OR was seen for glioma in the
highest category of TCSE 7+ years before diagnosis (OR 1.91,
95% CI 1.05 to 3.47), with an irregular but reasonably consistent
trend across TCSE categories (p¼0.01). There was no evidence of
increased risk for more recent exposures. Results for meningioma
were similar, but without evidence of a trend with TCSE for
exposure 7+ years before diagnosis (p¼0.24) (table 3).
Table 4 shows the results of sensitivity analyses for associa-
tions of brain tumours with the highest quintile of TCSE. Using
tumour centre estimated by computer algorithm for all subjects
had little impact on the results. The ORs for glioma and
meningioma fell slightly when reported laterality was not taken
into account. Excluding subjects with improbable reported use
(>5 h/day) or with reported use of 450 MHz phones had no
effect on ORs in the highest quintile, while excluding subjects
with proxy interviews increased them slightly, particularly for
glioma. The OR in the highest quintile was greatest in analyses
excluding non-regular users (using the lowest quintile of TCSE
as the reference categorydsee also table AII) and analyses
restricted to subjects for whom images were available for
tumour localisation.
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digital) (table 4), ORs were increased somewhat for glioma in
the highest quintile of CSE in the 800e900 MHz frequency
range and the highest two quintiles in the 1800e1900 MHz
range. The OR for meningioma was also elevated in the highest
quintile in the 800e900 MHz range, but much reduced in the
highest quintile in the 1800e1900 MHz range. There was little
evidence of increased risk when considering analogue and digital
technologies separately, except possibly for analogue signals
with meningioma. These analyses are not independent,
however, as many subjects had used several different frequency
bands or technologies. Data were too sparse for meaningful
analyses of subjects who only used one frequency band or
system. ORs for glioma were above 1 in all countries except
Israel; CIs were wide; however, the p value for heterogeneity
across countries was 0.37. Country-speciﬁc ORs for meningioma
were more variable. There was little evidence of differences in
ORs between men and women.
For the caseecase analyses, there were 44 glioma cases and
135 meningioma cases located in the most exposed area of the
brain and 512 and 537 cases, respectively, located elsewhere.
Knowledge of SAR was used to deﬁne the two case groups, thus
Table 1 ORs for brain tumours with regular use of a mobile phone and cumulative mobile phone call time in all eligible subjects, subjects with tumour
localisation data and subjects with tumour centre estimated by a neuroradiologist*
All subjects matched to controls or case
interviewed within 1 year
Subjects with tumour centre estimated by
a neuroradiologist or computer algorithmy
Only subjects with tumour centre estimated
by a neuroradiologist
Cases Controls OR (95% CI) Cases Controls OR (95% CI) Cases Controls OR (95% CI)
Glioma
Regular use
Never regular user 266 834 1.00 196 617 1.00 117 361 1.00
Regular user 542 1629 0.92 (0.75 to 1.13) 355 1103 0.93 (0.73 to 1.18) 209 565 1.06 (0.77 to 1.47)
Cumulative call time without hands-free devices (h)
Never regular user 266 834 1.00 196 617 1.00 117 361 1.00
<13.0 69 234 0.88 (0.63 to 1.24) 44 174 0.83 (0.55 to 1.26) 25 102 0.81 (0.46 to 1.42)
13.0e60.9 103 327 0.93 (0.69 to 1.25) 68 223 0.93 (0.65 to 1.32) 46 134 1.11 (0.71 to 1.75)
61.0e199.9 110 383 0.74 (0.55 to 0.99) 63 264 0.66 (0.46 to 0.96) 39 136 0.81 (0.5 to 01.33)
200e734.9 123 367 0.94 (0.71 to 1.26) 90 237 1.07 (0.76 to 1.50) 46 110 1.03 (0.64 to 1.67)
735+ 137 318 1.17 (0.88 to 1.56) 90 205 1.25 (0.88 to 1.77) 53 83 1.72 (1.07 to 2.77)
Meningioma
Regular use
Never regular user 356 807 1.00 294 643 1.00 157 398 1.00
Regular user 486 1 541 0.80 (0.66 to 0.96) 381 1153 0.77 (0.63 to 0.95) 186 648 0.77 (0.58 to 1.03)
Cumulative call time without hands-free devices (h)
Never regular user 356 807 1.00 294 643 1.00 157 398 1.00
<13.0 102 247 0.86 (0.64 to 1.15) 80 198 0.84 (0.60 to 1.16) 43 117 0.87 (0.56 to 1.34)
13.0e60.9 101 301 0.79 (0.60 to 1.04) 82 225 0.80 (0.59 to 1.10) 46 137 0.80 (0.53 to 1.22)
61.0e199.9 97 347 0.71 (0.53 to 0.94) 73 257 0.64 (0.46 to 0.89) 35 156 0.61 (0.39 to 0.96)
200e734.9 89 349 0.69 (0.51 to 0.93) 67 265 0.63 (0.45 to 0.88) 29 141 0.57 (0.35 to 0.94)
735+ 97 297 1.01 (0.75 to 1.36) 79 208 1.06 (0.75 to 1.48) 33 97 1.30 (0.79 to 2.15)
*Analyses based on unconditional logistic regression stratiﬁed on age, sex and region and adjusted for education and timing of interview.
yOrigin is as estimated by a neuroradiologist when available or as estimated by computer algorithm otherwise.
Table 2 ORs for brain tumours with level of total cumulative speciﬁc radio frequency energy (total
cumulative speciﬁc energy) (in joules per kilogram)*
Subjects with tumour centre estimated by
a neuroradiologist or computer algorithmy
Only subjects with tumour centre estimated
by a neuroradiologist
Cases Controls OR (95% CI) Cases Controls OR (95% CI)
Glioma
Never regular user 196 617 1.00 117 361 1.00
<76.7 67 265 0.76 (0.53 to 1.09) 36 150 0.84 (0.51 to 1.36)
76.7e 68 227 0.94 (0.66 to 1.35) 43 128 1.00 (0.62 to 1.60)
284.1e 60 207 0.80 (0.54 to 1.18) 39 102 1.15 (0.69 to 1.90)
978.9e 57 197 0.89 (0.61 to 1.30) 34 99 0.92 (0.55 to 1.53)
3123.9+ 103 207 1.35 (0.96 to 1.90) 57 86 1.66 (1.03 to 2.67)
Meningioma
Never regular user 294 643 1.00 156 396 1.00
<76.7 103 261 0.90 (0.67 to 1.21) 51 150 0.86 (0.57 to 1.29)
76.7e 71 199 0.74 (0.53 to 1.04) 47 127 0.95 (0.62 to 1.44)
284.1e 56 233 0.56 (0.39 to 0.80) 29 136 0.53 (0.32 to 0.87)
978.9e 62 209 0.72 (0.51 to 1.02) 23 117 0.55 (0.32 to 0.93)
3123.9+ 88 251 0.90 (0.66 to 1.24) 35 114 1.01 (0.63 to 1.62)
*Analyses based on unconditional logistic regression stratiﬁed on age, sex and region and adjusted for education and timing of
interview.
yCentre is as estimated by a neuroradiologist when available or as estimated by computer algorithm otherwise.
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for glioma in the highest exposed area were higher in long-term
users than in short-term users (OR 2.80, 95% CI 1.13 to 6.94 for
10 years or more of use). While OR for glioma tended to increase
with increasing call time to the fourth quintile, it was 0.99 in
the highest quintile (table 5). For meningioma, ORs were
highest in long-term and heavy users, but CIs were wide.
DISCUSSION
We have presented results of a ﬁrst attempt to analyse brain
tumour risk in relation to amount of RF absorbed by the brain
from use of a mobile phone held to the ear. In principle,
a measure of absorbed RF should be a more accurate indicator of
RF exposure to neural tissue than just mobile phone use and
enhance our ability to detect causal associations that might exist
between exposure to mobile phone RF ﬁelds and brain tumours.
Although our estimate of RF dose takes into account reported
phone use (which is subject to recall bias and uncertainties
28), it
also incorporates objective parameters (location of tumour,
frequency band and characteristics of communication systems),
not inﬂuenced by the interviewees recall, which affect the
amount of RF energy received at the tumour location.
24 The
localisation of tumours, necessary for accurate estimation of
relevant RF absorption, made our caseecase analysis by regions
of the brain possible.
Overall, there was weak evidence of stronger associations of
glioma and meningioma when a comprehensive estimate of RF
dose rather than just mobile phone use was used in the casee
control analysis. For glioma, the OR for the highest quintile of
TCSE was 1.35; that for the highest quintile of cumulative call
time was 1.25. There was a similar pattern for meningioma.
There are several possible explanations for this comparative lack
of increase in ORs using TCSE: observations of increased brain
tumour risk with mobile phone use are due to biases, and there
is no true association between mobile phone RF and brain
tumours; the associations of brain tumours with TCSE are
greatly weakened by sources of uncertainty in our dose esti-
mates; or a metric other than the absorbed energy better reﬂects
the carcinogenic mechanism.
24 Furthermore, the small increases
observed could be due to confounding of RF absorption with
pulsed extremely low frequency (ELF) magnetic ﬁelds from
digital phones.
24 There is little support for this, though, when
we compare ORs for analogue and digital systems (table 4) or in
our caseecase analyses in which the most exposed region was
deﬁned on the basis of RF absorption, which is much more
localised than ELF absorption. With respect to the performance
of TCSE as a dose measure, it should be noted that while
cumulative call time contributed to the calculation of TCSE and
there was moderate agreement between the two measures, there
was important residual variation due to the inclusion of
measures of RF absorption in TCSE.
24 It is thus possible that
investigation of different dose metrics and quantiﬁcation of
related uncertainties may yet improve RF dose estimation.
24
The results of our caseecase analysis show a moderately
strong association of glioma with mobile phone use that started
10+ years before diagnosis, OR 2.80, and little increase with
shorter latency. Because of the nature of the caseecase analyses,
bias due to differential participation of cases and controls is ruled
out; systematic differences in recall between cases with tumours
in the heavily exposed region of the brain and those with
tumours in the less heavily exposed region seem improbable
since cases are not aware of exact tumour location and its
meaning regarding exposure. The comparatively small number
of subjects from ﬁve countries on which this analysis is based
makes the results of the present caseecase analysis much more
uncertain than they would be if based on Interphone as a whole.
We also observed evidence of increased glioma risk with a long
latent period after ﬁrst use of a mobile phone in our standard
caseecontrol study analysis. The OR for glioma in the highest
quintile of TCSE was 1.91 for exposure beginning 7+ years in
the past (numbers of subjects by quintile of TCSE were too small
for meaningful analyses of exposures 10+ years in the past), and
Table 3 ORs for glioma and meningioma with level of total cumulative speciﬁc energy exposure (in joules per kilogram) in different windows of time
before diagnosis of the case in subjects with probable tumour centre estimated by a neuroradiologist or computer algorithm*
Glioma Meningioma
Cases Controls OR (95% CI) Cases Controls OR (95% CI)
<3 years in the past
Never regular user in this time period 206 647 1.00 300 667 1.00
<76.7 111 350 0.88 (0.61 to 1.26) 128 353 0.81 (0.59 to 1.11)
76.7e 72 271 0.63 (0.41 to 0.96) 84 252 0.79 (0.54 to 1.14)
284.1e 75 224 0.73 (0.46 to 1.16) 67 259 0.69 (0.46 to 1.04)
978.9e 40 141 0.56 (0.32 to 0.99) 51 144 0.92 (0.57 to 1.47)
3123.9+ 47 87 1.29 (0.68 to 2.47) 46 126 0.86 (0.49 to 1.53)
3e6 years in the past
Never regular user in this time period 270 917 1.00 417 962 1.00
<76.7 60 218 1.05 (0.69 to 1.61) 79 211 1.09 (0.75 to 1.56)
76.7e 64 170 1.36 (0.88 to 2.11) 41 168 0.73 (0.46 to 1.15)
284.1e 51 167 1.04 (0.62 to 1.75) 45 180 0.93 (0.58 to 1.50)
978.9e 49 132 1.14 (0.65 to 2.01) 48 132 1.08 (0.65 to 1.78)
3123.9+ 57 116 0.97 (0.49 to 1.93) 46 148 0.76 (0.40 to 1.43)
7+ years in the past
Never regular user in this time period 421 1445 1.00 586 1493 1.00
<76.7 20 63 1.11 (0.61 to 2.02) 28 81 1.07 (0.64 to 1.78)
76.7e 23 53 1.53 (0.85 to 2.78) 8 49 0.74 (0.33 to 1.67)
284.1e 24 53 1.50 (0.81 to 2.78) 17 68 0.88 (0.47 to 1.64)
978.9e 25 49 1.69 (0.91 to 3.13) 16 59 1.00 (0.52 to 1.92)
3123.9+ 38 57 1.91 (1.05 to 3.47) 21 51 2.01 (1.03 to 3.93)
*Unconditional logistic regression analyses stratiﬁed on age, sex and region and adjusted for education and timing of interview. Centre is taken to be as estimated by a neuroradiologist where
available and as estimated by computer algorithm otherwise. Associations in each time window are adjusted for associations in each other window.
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Original articlethere was evidence of a trend towards increasing risk with
increasing exposure. Lack of such a trend has been a consistent
feature of Interphone analyses of risk of glioma and may suggest
that increased ORs in the highest cumulative mobile phone use
category are due to observed greater overestimation of more
distant past mobile phone use by cases than controls.
29 The
apparent doseeresponse relationship for exposure 7+ years ago,
however, suggests that bias is not a sufﬁcient explanation for the
increased OR in the highest TCSE category, at least in this
exposure period, and suggests that the increased OR seen in the
highest category of use in the Interphone report is valid. These
results also suggest that if there is a real effect of RF on brain
tumour risk, a combination of a minimum latent period and
amount of exposure may be needed for an increased risk to be
observable (it is of note that the highest category of use in this
study, 735 h or more corresponds to about 12e13 min of use
a day over 10 years).
A number of caseecontrol studies, including Interphone,
28
have reported stronger associations with phone use on the
side of the head with the tumour. We dealt with exposure
laterality in the present analysis by allocating 90% of reported
phone use to the preferred side of phone use and 10% to the
other side when there was a preferred side (87% of cases and
91% of controls); otherwise, 50% was allocated to each side. In
a sensitivity analysis in which we allocated 50% to each side
in all subjects, the ORs for glioma and meningioma in the
highest quintile of TCSE averaged over the whole tumour
were only slightly reduced (table 4). Like comparisons of ORs
for RF absorption with cumulative mobile phone use, this
lack of marked change in OR may indicate that estimation of
RF absorption has not greatly improved overall exposure
ascertainment in this study. It also suggests that the increased
glioma ORs are not sensitive to errors in recall of laterality
of mobile phone use, which is suggested also by our casee
case analyses in which laterality of use was not taken into
account.
Associations observed with higher levels of TCSE exposure
are much weaker for meningioma than glioma, being barely
evident with TCSE in the caseecontrol analyses except in the
highest category in those ﬁrst exposed 7+ years before diag-
nosis (table 3). The ORs for meningioma in intermediate TCSE
exposure categories are also sometimes much less than those for
glioma (tables 2 and 3) and below unity. We have no certain
explanation for these differences, except that they could
suggest biases affecting results for both tumours (more for
meningioma), a causal association of mobile phone RF with
both (stronger for glioma than for meningioma) or, perhaps,
a shorter latency for glioma occurrence.
Table 4 Results of sensitivity analyses on ORs for glioma and meningioma with radio frequency exposure in the highest quintile of total cumulative
speciﬁc energy (TCSE)
Factors included in sensitivity analyses
Glioma Meningioma
Cases Controls OR (95% CI) Cases Controls OR (95% CI)
All subjects with tumour localisation
TCSE at centre of tumour
Estimated by neuroradiologists when available, predicted by computer
algorithm otherwisedmain analysis
103 207 1.35 (0.96 to 1.90) 88 251 0.90 (0.66 to 1.24)
Predicted by computer algorithm for all subjects 99 206 1.32 (0.93 to 1.86) 93 253 0.93 (0.68 to 1.27)
Estimated by neuroradiologists when available, predicted by computer
algorithm otherwise not taking account of tumour laterality
105 241 1.23 (0.89 to 1.72) 94 288 0.84 (0.62 to 1.15)
TCSE averaged over the entire tumour
Taking into account reported tumour laterality 107 224 1.28 (0.92 to 1.80) 93 253 0.92 (0.69 to 1.24)
Not taking into account tumour laterality 111 254 1.21 (0.87 to 1.68) 94 291 0.84 (0.61 to 1.15)
Effect of exclusion of
Subjects with very high reported use (>5 h/day) 93 188 1.34 (0.94 to 1.91) 81 235 0.91 (0.66 to 1.26)
Subjects with proxy response 94 207 1.43 (0.99 to 2.05) 87 249 0.93 (0.68 to 1.27)
Subjects reporting use of 450 MHz telephones 101 202 1.35 (0.96 to 1.91) 88 246 0.92 (0.67 to 1.26)
Never regular users (using the lowest quintile of TCSE as
reference category)
103 195 1.93 (1.26 to 2.96) 88 237 1.04 (0.71 to 1.53)
By frequency band
800e900 MHz 100 197 1.36 (0.96 to 1.93) 88 240 1.35 (0.74 to 2.44)
1800e1900 MHz 22 57 1.45* (0.80 to 2.63) 6 59 0.28 (0.10 to 0.79)
By communication system
Analogue 43 82 1.22 (0.77 to 1.92) 27 109 1.29 (0.71 to 2.34)
Digital 79 194 1.22 (0.84 to 1.76) 87 214 0.87 (0.45 to 1.67)
Only subjects with centre estimated by neuroradiologists
Using centre estimated by neuroradiologist 57 86 1.66 (1.03 to 2.67) 35 114 1.01 (0.63 to 1.62)
Using centre predicted by computer algorithm for all subjects 53 85 1.58 (0.98 to 2.57) 39 118 1.02 (0.64 to 1.61)
Only subjects for whom images were available (ie, excluding Israel) 70 109 1.82 (1.20 to 2.76) 33 113 1.23 (0.76 to 2.00)
Country-speciﬁc estimates
Australia 30 49 1.15 (0.56 to 2.38) 19 67 0.75 (0.38 to 1.48)
Canada 21 27 3.48 (1.63 to 7.43) 7 33 1.51 (0.58 to 3.93)
France 11 29 1.39 (0.56 to 3.49) 7 29 0.77 (0.30 to 1.98)
Israel 33 98 0.74 (0.40 to 1.37) 50 116 0.74 (0.47 to 1.17)
New Zealand 8 4 3.69 (0.78 to 17.5) 5 6 5.52 (0.98 to 31.2)
Sex-speciﬁc estimates
Men 85 133 1.33 (0.87 to 2.03) 41 151 0.98 (0.58 to 1.65)
Women 18 74 1.30 (0.69 to 2.47) 47 100 0.88 (0.58 to 1.34)
*OR in fourth quintile: 1.86, 95% CI 1.07 to 3.22 (29 cases and 54 controls).
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relevant exposure, which we presume to be mobile phone RF
energy absorbed at the tumour location when the phone is in use
near the ear. It is a weakness, though, that tumour localisation
was only available for about half the cases. Small increases in
strengths of associations when comparing results for TCSE with
those for cumulative phone use suggest that there was a small
increase in measurement accuracy (assuming a causal associa-
tion) from estimation of RF dose at the tumours’ centres. This
suggestion is supported by the further increases in ORs when
only tumours for which a neuroradiologist had estimated the
centre were included in analyses. However, this analysis
excluded Israeli subjects, for which the OR for any use of
a mobile phone was less than that for the other four centres (OR
without Israel 1.06), which weakens this inference. Further-
more, when neuroradiologists estimates of the centre were
replaced by computer generated estimates, the OR for glioma in
the highest category of TCSE fell only from 1.66 to 1.58. Thus
neuroradiologists’ localisations of the centre at the tumour’s
centre of gravity may have been no more accurate than the
computer algorithms.
The association of glioma with estimated TCSE seemed to be
robust against subjects’ recall of implausibly high mobile
phone use: exclusion of those with use >5 h reduced the OR
minimally from 1.35 to 1.34. In contrast, in Interphone as
a whole, the reduction was from 1.40 to 1.27. While this
difference might be due to different exposure measures, it could
also be due to the use of a subset of Interphone countries in this
analysis.
Generally speaking, results of our analyses are similar to
comparable analyses based on all Interphone centres.
28 One
other study, from Sweden, has investigated associations of
mobile phone use with brain tumour risk based on tumours
diagnosed over a period, 2000 to 2003, nearly the same as
Interphone, 2000 to 2004.
9 That study found increased risks of
malignant brain tumours (mostly gliomas) with any use of
analogue or digital mobile phones or cordless phones; risk was
generally increased in both low- and high-exposure categories,
evident with exposure 1e5 years before diagnosis and increasing
with intensity of exposure in time intervals more distant from
diagnosis. Our results are different from this study’s results
with respect to the apparent limitation of an association
between exposure and glioma in our data to higher exposures
and exposures occurring 7+ or 10+ years before diagnosis.
Our use of estimates of RF energy absorbed in the brain as
indicators of dose in analyses of associations of brain tumour
occurrence with mobile phone use may have increased the
strength of some positive associations otherwise observable
between these tumours and estimated cumulative use of a
mobile phone. Although subject to considerable uncertainty, our
analyses suggest that there is an increase in glioma risk with
higher levels of RF dose in people whose brain has absorbed
high levels of RF energy from mobile phone use and that this
risk may only be evident in people who began mobile phone
use 7e10 years or more before diagnosis. There is a possibility
also of similar, but apparently much smaller, increases in
meningioma risk. Uncertainties around these results require that
they are replicated before they can be considered to be real. The
best way to replicate them would be to repeat this analysis in
data from the other eight Interphone countries and in future
studies with longer latency periods and higher cumulative
exposures.
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*Treated as ‘cases’.
yTreated as ‘controls’.
zQuintiles of cumulative call time among ‘controls’ (glioma cases with tumour centre outside the most exposed area). Centre is as estimated by a neuroradiologist when available or as
estimated by computer algorithm otherwise. Unconditional logistic regression analyses were done, stratiﬁed on age, sex and region and adjusted for education and timing of interview.
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APPENDIX
Table AI Distributions of glioma and meningioma cases and controls ascertained, interviewed and matched and with data available for analysis
Glioma
Total
ascertained Interviewed
Matched to case or
controls interviewed
within 1 year
Cases with tumour localisation data and their matched controls
Centre estimated by
neuroradiologist or
computer algorithm
As in preceding column
and have information about
communication system
and frequency band
Centre estimated
by neuroradiologist
As in preceding column
and have information about
communication system
and frequency band
Cases
Total 1302 829 809 567 553 339 329
Australia 536 301 295 142 142 141 141
Canada 273 170 170 158 144 110 100
France 155 94 94 68 68 56 56
Israel 206 180 168 163 163 0 0
New Zealand 132 84 82 36 36 32 32
Controls
Total 4838 2565 2496 1877 1762 1032 958
Australia 1608 669 669 328 317 327 316
Canada 1330 653 633 581 492 348 296
France 639 472 459 331 328 294 291
Israel 911 599 587 566 562 0 0
New Zealand 350 172 148 71 63 63 55
Meningioma
Total
ascertained Interviewed
Matched to controls
or case interviewed
within 1 year
Cases with tumour localisation data and their matched controls
Tumour centre
estimated by
neuroradiologist or
computer algorithm
As in preceding column
and have information about
communication system
and frequency band
Tumour centre
estimated by
neuroradiologist
As in preceding column
and have information about
communication system
and frequency band
Cases
Total 1199 895 842 688 676 349 343
Australia 413 254 250 158 158 155 155
Canada 134 94 94 82 71 56 50
France 190 145 144 116 116 109 109
Israel 390 350 306 303 302 0 0
New Zealand 72 52 48 29 29 29 29
Controls
Total 4838 2565 2464 2015 1911 1213 1142
Australia 1608 669 667 431 413 417 400
Canada 1330 653 613 540 466 342 295
France 639 472 458 379 376 358 356
Israel 911 599 591 569 565 0 0
New Zealand 350 172 135 96 91 96 91
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Original articleFigure AI Spatial deposition of radio frequency (RF) energy in the
Gridmaster cellsdthe light cubes identify the most exposed region of
the brain, that is, that with the highest speciﬁc absorption rate of RF
energy from mobile phones. The dark cubes identify the less exposed
area of the brain. The most exposed area (light cubes) correspond to
about 16% of the brain volume and absorbs >50% of the total RF energy
in the brain from mobile phones used at the ear.
Figure AII Distribution of glioma
cases and controls by level of total
cumulative speciﬁc energy (TCSE) (in
joules per kilogram) at the estimated
centre of the tumour; centre is taken to
be as estimated by neuroradiologist,
where available, and as estimated by
computer algorithm otherwise.
Table AII ORs for brain tumours with level of total cumulative speciﬁc
RF energy (TCSE) exposure (in joules per kilogram) in subjects with
tumour centre estimated by a neuroradiologist or computer algorithm,
excluding non-regular users. n these analyses, the lowest quintile of
TCSE is used as the reference category
Subjects with tumour centre estimated by
a neuroradiologist or computer algorithm
Cases Controls OR (95% CI)
Glioma
<76.7 65 241 1.00
76.7e 68 213 1.34 (0.86 to 2.08)
284.1e 60 198 1.13 (0.71 to 1.79)
978.9e 57 191 1.22 (0.77 to 1.93)
3123.9+ 103 195 1.93 (1.26 to 2.96)
Meningioma
<76.7 96 231 1.00
76.7e 71 194 0.86 (0.58 to 1.27)
284.1e 56 221 0.63 (0.41 to 0.95)
978.9e 62 199 0.87 (0.58 to 1.31)
3123.9+ 88 237 1.04 (0.71 to 1.53)
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